00:35 , Feb 9, 2019 |  BC Extra  |  Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...
01:52 , Feb 8, 2019 |  BC Week In Review  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
23:45 , Feb 7, 2019 |  BC Extra  |  Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
00:52 , Feb 1, 2019 |  BC Week In Review  |  Company News

Celgene gains option for Triphase's epigenetic cancer therapy

Celgene Corp. (NASDAQ:CELG) has acquired another option for a cancer program ahead of its acquisition by Bristol-Myers Squibb Co. (NYSE:BMY), this time via a deal with Triphase Accelerator Corp. (Toronto, Ontario). On Jan. 29, Celgene...
20:16 , Jan 29, 2019 |  BC Extra  |  Company News

Celgene gains option for Triphase's epigenetic cancer therapy

Celgene Corp. (NASDAQ:CELG) has acquired another option for a cancer program ahead of its acquisition by Bristol-Myers Squibb Co. (NYSE:BMY), this time via a deal with Triphase Accelerator Corp. (Toronto, Ontario.) On Tuesday, Celgene gained...
23:50 , Jan 28, 2019 |  BC Extra  |  Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
04:01 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Microbiome company Vedanta raises $27M series C round

With $27 million in new series C funding, microbiome company Vedanta Biosciences Inc. (Cambridge, Mass.) intends to fund a handful of clinical trials to treat food allergies, cancer and bacterial infections. Investors included the Bill...